Industry

IRVING, Texas & ASHEVILLE, N.C.–(BUSINESS WIRE)–The Consortium of Independent Immunology Clinics (CIIC), a professional medical organization comprised of select Board-Certified Allergists and Immunologists in private practice in 21 states throughout the USA, is proud to announce the addition of Allergy Partners, PLLC as its 25th member to the network. Allergy Partners is the nation’s largest … [Read more…]

Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 … [Read more…]

PRINCETON, N.J. & OVERLAND PARK, Kan.–(BUSINESS WIRE)–WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research’s (DVCR) industry-leading, green-designed research … [Read more…]

Submissions based on data from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented at ASCO 2022 The ATHENA-MONO trial met its primary endpoint, showing Rubraca monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Safety of … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program … [Read more…]

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #AZBio–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received an AZBio Fast Lane Award from the Arizona Bioindustry Association (AZBio). “Castle Biosciences is working to transform how diseases are managed with the goal of making life better for patients,” … [Read more…]

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Virtual Life Sciences Investor Forum on Thursday, September 15, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific Time). Management will be holding investor one-on-one meetings on … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Virtuoso Surgical, Inc., a Nashville-based medical device company, announced today that its $20 million stock offering has become effective after review by the United States Securities and Exchange Commission and the Financial Industry Regulatory Authority. Virtuoso Surgical has developed a robotic surgery system that radically improves minimally invasive endoscopic surgery. Virtuoso uses patented … [Read more…]

Critical upgrades allow the Company to produce SPC-069 drug substance for clinical trials Other new additions to the facility include dedicated quality control room, microbiology laboratory and office space KNUTSFORD, England–(BUSINESS WIRE)–SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the Company … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act … [Read more…]